Tue, September 17, 2019
Mon, September 16, 2019
Fri, September 13, 2019
Thu, September 12, 2019

Marc Goodman Upgraded (ACAD) to Buy and Increased Target to $50 on, Sep 13th, 2019

Marc Goodman of SVB Leerink, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Buy and Increased Target from $21 to $50 on, Sep 13th, 2019.

Marc has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 1 agrees with Marc's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $28 on, Tuesday, September 3rd, 2019


These are the ratings of the 4 analyists that currently disagree with Marc


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy on, Tuesday, September 10th, 2019
  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $60 on, Monday, September 9th, 2019
  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $40 on, Tuesday, August 27th, 2019
  • Danielle Brill of "Raymond James" Reiterated at Strong Buy with Increased Target to $43 on, Friday, May 31st, 2019